Research reveals YTHDF2 promotes metastasis in nasopharyngeal carcinoma by regulating FOXO1, suggesting it as a potential therapeutic target and biomarker.
YTHDF2 potentially functions as an oncogene in NPC by binding to the m6A site of FOXO1, reducing its expression, thereby promoting malignant behavior. It may also be a viable biomarker and therapeutic target for NPC.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: